blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3666275

EP3666275 - COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  16.07.2021
Database last updated on 27.07.2024
FormerThe application has been published
Status updated on  15.05.2020
Most recent event   Tooltip16.07.2021Application deemed to be withdrawnpublished on 18.08.2021  [2021/33]
Applicant(s)For all designated states
Pharma Mar, S.A.
Avda. de los Reyes, 1
Polígono Industrial La Mina-Norte
28770 Colmenar Viejo, Madrid / ES
[2020/25]
Inventor(s)01 / MONEO OCAÑA, Victoria
Pharma Mar, S.A
Avda. de los Reyes 1
Polígono Industrial La Mina-Norte
E-28770 Colmenar Viejo, Madrid / ES
02 / SANTAMARÍA NÚÑEZ, Gema
Pharma Mar, S.A.
Avda. de los Reyes, 1
Polígono Industrial La Mina-Norte
E-28770 Colmenar Viejo, Madrid / ES
03 / GARCÍA FERNÁNDEZ, Luis Francisco
Pharma Mar, S.A
Avda. de los Reyes 1
Polígono Industrial La Mina-Norte
E-28770 Colmenar Viejo, Madrid / ES
04 / GALMARINI, Carlos María
Pharma Mar, S.A
Avda. de los Reyes 1
Polígono Industrial La Mina-Norte
E-28770 Colmenar Viejo, Madrid / ES
05 / GUILLÉN NAVARRO, María José
Pharma Mar, S.A
Avda. de los Reyes 1
Polígono Industrial La Mina-Norte
E-28770 Colmenar Viejo, Madrid / ES
06 / AVILÉS MARÍN, Pablo Manuel
Pharma Mar, S.A
Avda. de los Reyes 1
Polígono Industrial La Mina-Norte
E-28770 Colmenar Viejo, Madrid / ES
 [2020/25]
Representative(s)ABG Intellectual Property Law, S.L.
Avenida de Burgos, 16D
Edificio Euromor
28036 Madrid / ES
[2020/25]
Application number, filing date20155618.011.11.2011
[2020/25]
Priority number, dateEP2010038230012.11.2010         Original published format: EP 10382300
[2020/25]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3666275
Date:17.06.2020
Language:EN
[2020/25]
Type: A3 Search report 
No.:EP3666275
Date:09.09.2020
Language:EN
[2020/37]
Search report(s)(Supplementary) European search report - dispatched on:EP10.08.2020
ClassificationIPC:A61K31/4995, A61K31/69, A61K45/06, A61K38/15, A61P35/00, A61P35/02, A61K31/513, A61K31/519, A61K31/7068
[2020/25]
CPC:
A61K31/4995 (EP,CN,KR,RU,US); A61K45/06 (EP,CN,KR,US); A61K31/337 (EP,KR,US);
A61K31/34 (RU); A61K31/395 (RU); A61K31/4164 (EP,KR,US);
A61K31/4188 (EP,KR,US); A61K31/4375 (EP,KR,US); A61K31/513 (EP,CN,KR,US);
A61K31/519 (EP,CN,KR,US); A61K31/55 (EP,US); A61K31/69 (EP,CN,KR,US);
A61K31/704 (EP,US); A61K31/7068 (EP,KR,US); A61K33/243 (EP,CN,US);
A61K38/15 (EP,CN,KR,US); A61P1/04 (EP); A61P1/16 (EP);
A61P1/18 (EP); A61P11/00 (EP,US); A61P13/08 (EP);
A61P13/10 (EP); A61P13/12 (EP); A61P15/00 (EP);
A61P17/00 (EP); A61P21/00 (EP); A61P25/00 (EP);
A61P3/00 (EP); A61P35/00 (EP,RU,US); A61P35/02 (EP);
A61P43/00 (EP); Y02A50/30 (EP) (-)
C-Set:
A61K31/4995, A61K2300/00 (US,CN,EP);
A61K31/513, A61K2300/00 (US,CN,EP);
A61K31/519, A61K2300/00 (US,CN,EP);
A61K31/69, A61K2300/00 (US,CN,EP);
A61K31/7068, A61K2300/00 (EP,US);
A61K38/15, A61K2300/00 (CN,EP,US)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/25]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KOMBINATIONSTHERAPIE MIT EINEM ANTITUMORALEN ALKALOID[2020/25]
English:COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID[2020/25]
French:THÉRAPIE DE COMBINAISON AVEC UN ALCALOÏDE ANTITUMORAL[2020/25]
Examination procedure10.03.2021Application deemed to be withdrawn, date of legal effect  [2021/33]
30.03.2021Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2021/33]
Parent application(s)   TooltipEP11781807.0  / EP2637663
EP14175282.4  / EP2786756
Fees paidRenewal fee
05.02.2020Renewal fee patent year 03
05.02.2020Renewal fee patent year 04
05.02.2020Renewal fee patent year 05
05.02.2020Renewal fee patent year 06
05.02.2020Renewal fee patent year 07
05.02.2020Renewal fee patent year 08
05.02.2020Renewal fee patent year 09
27.11.2020Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]EP1806349  (PHARMA MAR SA [ES]) [Y] 1-6,14,15 * p. 19, compound 27; paragraphs [0037], [0063]-[0071] *;
 [A]WO2009140675  (PHARMA MAR SA [ES], et al) [A] 1-6,14,15 * claim 13 *;
 [Y]  - JFM LEAL ET AL, "PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity", BRITISH JOURNAL OF PHARMACOLOGY, (20100702), vol. 161, no. 5, doi:10.1111/j.1476-5381.2010.00945.x, ISSN 0007-1188, pages 1099 - 1110, XP055013260 [Y] 1-6,14,15 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1476-5381.2010.00945.x
 [Y]  - Manuel M Paz, "Antitumour Antibiotics", Anticancer Therapeutics, (20080101), doi:10.1002/9780470697047.ch8, ISBN 978-0-47-072303-6, XP055139812 [Y] 1-6,14,15 * the whole document *

DOI:   http://dx.doi.org/10.1002/9780470697047.ch8
 [Y]  - G. MINOTTI, "Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity", PHARMACOLOGICAL REVIEWS, (20040601), vol. 56, no. 2, doi:10.1124/pr.56.2.6, ISSN 0031-6997, pages 185 - 229, XP055139671 [Y] 1-6,14,15 * the whole document *

DOI:   http://dx.doi.org/10.1124/pr.56.2.6
 [XP]  - José Guillén ET AL, "In vivo combination studies of PM01183 with alkylating, antimetabolites, DNA-topoisomerase inhibitors and tubulin binding agents", (20110405), URL: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=17ec9ca9-693a-4df8-8e8c-857ab3e72dc7&cKey=09c40d0f-78d3-44d9-bac5-c1117328e5c6&mKey={507D311A-B6EC-436A-BD67-6D14ED39622C}, (20120307), XP055021187 [XP] 1-6,14,15 * the whole document *
 [T]  - E Calvo, "Lurbinectedin (PM01183) in combination with doxorubicin (DOX): Preliminary results of a phase Ib study", European Journal of Cancer, Volume 49 Supplement 2, (20130901), URL: http://2013.europeancancercongress.org/Scientific-Programme/Abstract-search?abstractid=5425, (20140911), XP055139614 [T] * the whole document *
by applicantWO0187894
 WO03001427
 WO03014127
 WO2004035613
 WO2006046079
    - LEAL JFM et al., Br. J. Pharmacol., (20100000), vol. 161, pages 1099 - 1110
    - CHOU T.C., Pharmacol. Rev., (20060000), vol. 58, pages 621 - 681
    - CHOUTALALAY, Adv. Enzyme Regul., (19840000), vol. 22, pages 27 - 55
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.